Estimated glomerular filtration rate independently predicts outcome of azacitidine therapy in higher‐risk Myelodysplastic syndromes. Results from 536 patients of the Hellenic National Registry of Myelodysplastic and Hypoplastic syndromes. Issue 4 (26th June 2020)

• Record Type: Journal Article
• Authors: Papadopoulos, Vasileios; Diamantopoulos, Panagiotis T.; Papageorgiou, Sotirios G.; Papoutselis, Menelaos; Vrachiolias, George; Pappa, Vassiliki; Galanopoulos, Athanasios G.; Vassilakopoulos, Theodoros P.; Hatzimichael, Eleftheria; Zikos, Panagiotis; Papadaki, Helen A.; Bouchla, Anthi; Panayiotidis, Panayiotis; Megalakaki, Aekaterini; Papaioannou, Maria; Liapis, Konstantinos; Dryllis, George; Tsokanas, Dimitris; Kourakli, Alexandra; Symeonidis, Argiris; Viniou, Nora‐Athina; Kotsianidis, Ioannis
• Is Part Of: Hematological oncology. Volume 38:Issue 4(2020)
• Page Start: 541
• Page End: 553
• Publication Date: 2020-06-26
• Subjects: azacitidine -- clinical studies -- eGFR -- MDS; Hematological oncology -- Periodicals; Hematology; Medical Oncology; 616.99418005
• DOI: 10.1002/hon.2756
• Languages: English
• ISSNs: 0278-0232

Abstract

Abstract: Higher‐risk Myelodysplastic syndromes (MDS) patients undergoing treatment with 5‐azacytidine (AZA) are typically elderly with several comorbidities. However, the effect of comorbidities on the effectiveness and safety of AZA in real‐world settings remains unclear. We analyzed data from 536 AZA‐treated patients with higher‐risk MDS, Myelodysplastic/Myeloproliferative neoplasms and low blast count Acute Myeloid Leukemia enrolled to the Hellenic National Registry of Myelodysplastic and Hypoplastic Syndromes. Multivariate analysis adjusted also for the International Prognostic Scoring System (IPSS), its revised version (IPSS‐R) and the French Prognostic Scoring System (FPSS), demonstrated independent associations of overall and leukemia‐free survival with estimated glomerular filtration rate (eGFR) <45 mL min −1 /1.73 m 2 ( P = .039, P = .023, respectively), ECOG performance status <2 ( P = .015, P = .006), and presence of peripheral blood blasts ( P = .008, P = .034), while secondary MDS also correlated with significantly shorter leukemia‐free survival ( P = .039). Addition of eGFR <45 mL min −1 /1.73 m 2, in IPSS‐R and FPSS increased the predictive power of both models. Only FPSS ≤2 and eGFR <45 mL min −1 /1.73 m 2 predicted worse response to AZA in multivariate analysis, whereas eGFR <45 mL min −1 /1.73 m 2 correlated significantly with death from hemorrhage ( P = .003) and cardiovascular complications ( P = .006). In conclusion, in the second largest real‐world series of AZA‐treated MDS patients, we show that an eGFR <45 mL min −1 /1.73 m 2 is an independent predictor of worse response and survival. This higher cut‐off, instead of the commonly used serum creatinine >2 mg/dL, can be utilized as a more precise indicator of renal comorbidity during AZA therapy. Incorporation of eGFR in the prognostic assessment of AZA‐treated MDS patients may prove useful not only in routine practice, but also for the appropriate patient stratification in clinical trials with AZA combinations.